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Introduction. Two randomized studies on the use of a gentamicin-collagen sponge (GRM01/1997 and GRM02/2007) 
in rectal cancer surgery showed a statistically significant decrease in the rate of distant metastases in the experimental 
group and a similar rate of  local recurrences. The objective of the presented study was a retrospective evaluation of the 
effect of the GRM use on the observed rate of generalized recurrences, disease-free survival (DFS), overall survival (OS) and 
cancer-specific survival (CSS) – depending on the length of the interval between radiotherapy and surgery.
Materials and methods. The study comprised 239 patients, included previously into randomized studies, in whom the 
5 x 5 Gy radiotherapy was used. In 204 people, the surgery was made within 7 days of the completion of radiotherapy  
(group A). The remaining group of  35 patients were operated on after 4–8 weeks (group B). The follow-up period was 
5 years. The statistical analysis was made with the Kaplan-Meier test. The value of α = 0.05  was degfined as the threshold 
of statistical significance.   
Results. In both groups, there were no statistical differences between the patients operated on with the use of GRM and 
those operated on without the use of  GRM. The analysis took into consideration the most significant parameters, which 
could affect the oncological results,  (ypTNM, lympho-vascular invasion (LVI), blood vessel invasion (BVI). In group A, the 
use of GRM was connected with a lower rate of metachronic distant metastases (p = 0.002; RR 0.41; 95% CI [0.24–0.72]), 
the prolongation of DFS (p = 0.008; HR 2.16; 95% CI [1.20–3.83]) and of CSS (p = 0.010; HR 2.37; 95% CI [1.20–4. 67]). No 
such relationships were observed in group B.
Conclusions. The use of GRM decreases the risk of distant metastases and has an influence on the prolongation of recur-
rence free survival, but only when surgery is carried out within 7 days of the completion of irradiation. 
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Introduction 
The results of two randomized clinical studies (GRM01/1997 
and GRM02/2007) showed that intraoperative use of a gen-
tamicin-collagen sponge in rectal cancer patients, undergo-
ing preoperative radiotherapy, followed by radical tumour 
resection, decreases the risk of distant metastases [1, 2]. 
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The  objective of the first study (Nowacki et al.) [1] was to 
determine the effect of GRM on the risk of post-operative 
complications and oncological results. The surprising results 
of the 3-year long-term follow-up, showed a significantly lower 
rate of distant metastases in the group of patients operated 
on with the use of GRM inspired another  study with the 
objective to confirm the previous results (Rutkowski et al.) [2]. 
This time, the main objective of the project was to confirm the 
anti-cancer properties of GRM with regards to a reduction of 
generalized relapse. The study confirmed earlier observations: 
in the patient group with GRM, distant metastases occurred 
twice as rarely than in the control group (8.6% vs. 23.5%; HR 
2.4; 95% CI: 1.1–5.5; p = 0.005). 
Still, the mechanism of action of the studied medicinal 
product, which led to a decrease in the rate of generalized 
recurrence, is unknown. One of the considered hypothe-
ses is the correlation between the antibiotic (GRM), which 
has a local effect on the irradiated area and the previously 
used ionizing irradiation, with respect to the activation of 
immunological mechanisms. Radiotherapy, by means of 
affecting the micro-environment of the tumour, creates 
the potential to reverse immunosuppressive conditions 
present in cancer [3]. An important role here is played by 
a fractional dose of radiotherapy [4]. The objective of the 
presented study was to evaluate how the interval between 
the last fractional dose of radiotherapy and the surgery, 
affects oncological outcomes. 
Materials and methods  
The analysis concerned the data of the patients who partici-
pated in two randomized studies, completed and published. 
The criteria of participation were described before [1, 2]. Both 
studies concerned patients with rectal primary adenocarcino-
ma. The randomization was made with a 1:1 proportion, and 
the study group were those patients who, after resection of 
the tumour with mesorectum, had a GRM implanted into the 
pelvis. The same agent was used in both studies. The clinical 
stage of the cancer was evaluated on the basis of  the com-
puted tomography (CT) of the abdominal cavity and pelvis 
with the contrast medium administered intravascularly. In the 
period when the clinical material was collected (1997–1999 
and 2008–2011), magnetic resonance imaging (MRI) of the 
pelvis was not a diagnostic standard in the research centre. 
Qualification for the treatment was made on the basis of the 
multidisciplinary team’s decision. Radiotherapy with high frac-
tional doses (5 x 5 Gy) was applied in the case of resectable 
tumours with cT3–4 N0–2 M0 stage.  
The treatment standard was a radical resection within 
7  days of the completion of radiotherapy. The interval was 
prolonged only when there were medical contraindications 
for the surgery at the designed moment (e.g. an active infec-
tion, exacerbation of non-cancer related comorbidities). The 
surgeries were performed by one team of experienced sur-
geons. The operative technique was total mesorectum excision 
(TME). All the perioperative and post-operative complications, 
occurring within 30 days of surgery, were carefully reported. 
The pathomorphological assessment comprised: 
• histological type of the tumour, 
• TNM stage,
• radicality of the resection (R feature). 
Additionally, the second study also assessed:
• the stage of the primary tumour (ypT), 
• the condition of the regional lymph nodes (ypN), 
• tumour differentiation (G feature), 
• cancer invasion of lymphatic and/or blood vessels, 
• radicality of the mesorectum resection,
• the length of the resection margin. 
The data from the pathomorphological protocol, which 
were not routinely specified in the first study (Nowacki et al. 
[1]), were completed retrospectively. Patients with the third 
TNM stage of the disease also underwent adjuvant treatment 
(chemotherapy : 5 FU + LV, and, in the second study also OX + 
5 FU + LV). The long-term observation consisted of an eva-
luation of the clinical condition with the CEA determination:
• every 3 months – for the first 2 years after the surgery, 
• then – every 6 months – up to 5 years after the surgery. 
Imaging diagnostics of the abdominal cavity were perfor-
med routinely, once per year, or more frequently in the case 
when a relapse was suspected. A colonoscopy was a standard 
assessment in the third and fifth year postoperatively. The 
criterion for diagnosing local recurrence was the presence of 
a tumor in the pelvis or within the anastomosis. Distant me-
tastases were defined as the presence of tumors in any other 
location. If there was any doubt concerning the character of the 
observed lesions, then a biopsy and microscope verification 
were recommended.     
The selection criteria for this study are presented in figure 1. 
Patients undergoing preoperative radio-chemotherapy were 
excluded from the study as in the study period, this method of 
treatment was applied solely in patients with a primarily non-
-resectable tumour. Depending on the length of the interval 
between the completion of the irradiation and the surgery, 
two groups of patients were distinguished: 
• A: a short interval between the end of radiotherapy and 
surgery (the surgery was performed within 0–7 days from 
the completion of radiotherapy) – 204 patients,
• B: a long interval between the end of radiotherapy and 
surgery (the surgery was performed within 4–8 weeks from 
the completion of radiotherapy) – 35 patients. 
In both groups, instead of the randomization result, the 
clinical data concerning the actual use of GRM (or not) were 
taken into consideration. The comparative characteristics of 
both groups are presented in table I. The grade of the disease, 
determined on the basis of the histopathological assessment 
of the resected post-operative material in patients in group B 
was lower than in group A (p = 0.005). In 22 (63%) operated 
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Nowacki i wsp. [1]
n = 218
SELECTION CRITERIA: 
– resectable rectal adenocarcinoma 
– lower tumour border up to 12 cm from the edge of the anus 
– preoperative hyperfractionated radiotherapy (5 x 5 Gy)
– lack of synchronous distant metastases 
– radical TME resection 
– completed 5-year follow-up period 
– no preoperative radiotherapy (n = 102)
– presence of preoperative radiotherapy  (n = 35)
– synchronous distant metastases (n = 3)
– loss from the follow-up (n = 1)
Rutkowski i wsp. [2]
n = 162
 study group 
n = 239
Group A – the interval between the radiotherapy and 
the surgery up to 7 days (n = 204)
Group B – the interval between the radiotherapy and 
the surgery  4–8 weeks (n = 35)
Figure 1. Patient selection 
Table I. Comparative characteristics of the patients within the groups selected on the basis of the length of the interval between the completion of hyper-
fractionated radiotherapy and the surgery  
Patients' characteristics Group A n (%) Group B n (%) p







age: • median [range] 63 [25–84] 62 [38–81] 0.941
the distance between the tumour and the anus (cm) • median [range] 5 [0–12] 5 [1–10] 0.878
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GRM – gentamicin-collagen sponge; LAR – low anterior resection; AR – anterior resection; ASAR – abdominosacral amputation of the rectum; Hrtm. – Hartmann procedure 
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patients, after a long break, the grade was determined to be 
I or II. In 3 patients (9%), a complete pathomorphological remis-
sion was observed, which may be related to cancer remission 
observed after radiotherapy.  
The statistical analysis was made on the basis of actual use, 
or not, of GRM (per-protocol analysis) made in two subgroups 
of patients selected on the basis of the interval between radio-
therapy and surgery. The differences between the categorised 
variables  were assessed with the use of χ² test or Fisher’s exact 
test. Continuous variables were compared with the Mann-
-Whitney U-test. Overall survival (OS), disease free survival 
(DFS) and cancer specific survival (CCS) were assessed with 
the Kaplan-Meier method and compared with the long-rank 
test. The level of statistical significance was established in all 
the tests on the level of  α = 0.05.
Results 
GRM was applied in 102 (50%) patients in group A and in 19 
(54%) in group B. In both groups, there were no statistically 
significant differences between the operated patients with 
the use of GRM and the operated patients without the use 
of GRM. The comparison took into consideration the most 
important parameters which might affect the oncological 
results, such as: 
• ypTNM cancer stage (group A: p = 0.207; group B: p = 0.401), 
• lympho-vascular invasion (LVI) (group A: p = 0.865; group 
B: p = 0.182),  
• blood vessel invasion (BVI) (group A: p = 0.221; group B: 
p = 0.408) (tab. II). 
Metachronic distant metastases were observed in 48 
(23.5%) patients in group A and in 3 (8.6%) in group B (p = 0.07; 
Table II. Patients’ characteristics, taking into consideration the use of gentamicin-collagen sponge (GRM) 
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RR 2.75; 95% CI: 0.90–8.33). The use of GRM in operated pa-
tients within a short interval after the end of radiotherapy 
(group A) was connected with a lower rate of metachronic 
distant metastases (13.7% vs. 33.3%; p = 0.002; RR 0.,41; 95% CI: 
0.24–0.72). No similar relationship was observed in the case of 
surgery performed after a longer interval  (p = 1.000; RR 1.68; 
95% CI: 0.17–16.91).
Irrespective of the length of the interval between the end 
of radiotherapy and surgery, the application of GRM did not 
affect the rate of 5-year overall survival (group A: p = 0.484; 
HR 1.20; 95% CI: 0.72–1,99; group B: p = 0.956; HR 1.04; 95% 
CI: 0.23–4.66) (fig. 2). 
The use of GRM improved the 5-year disease free survival 
rate, but only in cases when the surgery was performed within 
7 days of the completion of radiotherapy (p = 0.008 HR 2.16; 
95% CI [1.20–3.83] vs. p = 0.892 HR 1.11; 95% CI [0.25–4.96]) 
(fig. 3). 
The analysis of 5-year cancer specific survival shows an 
improvement in results in the case of surgery performed after 
a short interval (group A) and the intraoperative use of  GRM 
(p = 0.010; HR 2.37; 95% CI: 1.20–4.67 vs. p = 0.820; HR 0.80; 
95% CI: 0.11–5.66) (fig. 4).
Discussion 
Long-term results of the randomized study carried out by the 
Dutch Colorectal Cancer Group, showed that a short-lasting 
radiotherapy with high fractionated doses connected with 
immediate TME radical resection, decrease the risk of local re-
currence of rectal cancer. This, however, does not translate into 
a prolongation of overall survival  [5]. Some studies suggested 
that the prolongation of the interval between the radiotherapy 
and surgery by >4 weeks in patients suffering from resectable 
rectal cancer in stage cT3N+, increases the rate of complete 
pathological remissions and overall survival [6]. 
The Stockholm III study has proven that a delay of surgery 
by 6–8 weeks after a short-lasting brachytherapy, increases the 
rate of clinical remissions, but does not affect the prolongation 
of overall survival  [7]. Two randomized studies which were 
carried out concerning the effect of the intraoperative use 
of GRM on the results of the treatment of patients with rectal 
cancer, showed a significant decrease in the risk of distant 
metastases, but the mechanism of anti-cancer action of the 
agent remained unknown [1,  2]. 
The objective of the current retrospective studies, based on 
the materials from the two randomized studies, was to explain 
whether the length of the interval between the completion of 
hyper-fractionated short-term preoperative radiotherapy had 
any effect on the obtained oncological results. Each time, the 
prolongation of the interval was only the result of the medical 
contraindications for the surgery performed immediately after 
the completion of radiotherapy. Therefore, the difference in the 
numbers of the two compared groups was  so high (group A: 
204 patients vs. group B: 35 patients). In those patients with 
a  delayed surgery, the disease stage as evaluated preoperative-
ly (ypTNM) was lower (p = 0.005) – this is shown in table I. The 




















GRM (+) 102 97 96 90 86 82 74
GRM (–) 102 100 96 88 80 74 70
GRM (+) 19 19 18 17 17 15 15
GRM (–) 16 16 14 14 14 13 13




















Figure 2. 5-year overall survival
 GRM (+): patient group with the use of the gentamicin-collagen sponge 
 GRM (–): patient group without  the use of the gentamicin-collagen sponge
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of the cancer [8]. The use of GRM in patients operated on after 
a short break  (group A) was connected with a lower rate of 
metachronic distant metastases (3.7% vs. 33.3%; p = 0.002). 
No similar relationship was observed in group B (p = 1.000). 
The improvement of the rate of 5-year disease free survival 
was seen solely in the case of the application of GRM in the 
patients operated on immediately after radiotherapy (group 




















GRM (+) 102 99 93 89 86 86 85
GRM (–) 102 96 85 77 71 68 67
GRM (+) 19 19 18 17 17 15 15
GRM (–) 16 14 14 14 14 13 13







































GRM (+) 102 102 102 98 97 94 90
GRM (–) 102 101 98 91 83 78 75
GRM (+) 19 19 19 19 18 17 17
GRM (–) 16 16 15 14 14 14 14




















Figure 3. 5-year disease free survival period
Figure 4. 5-year cancer specific survival period 
 GRM (+): patient group with the use of the gentamicin-collagen sponge 
 GRM (–): patient group without  the use of the gentamicin-collagen sponge
 GRM (+): patient group with the use of the gentamicin-collagen sponge 
 GRM (–): patient group without  the use of the gentamicin-collagen sponge
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survival. However, the analysis of cancer specific survival may 
suggest a beneficial anti-cancer effect of GRM, provided it is 
used during surgery performed immediately  (≤7 days) after 
the completion of irradiation. 
In spite of these encouraging results, the mechanism of 
anti-cancer activity of GRM remains unknown. Moreover, the 
fact that the observed anti-cancer effect of the application 
of this agent is stronger in the case of surgery performed 
immediately after the end of irradiation, cannot be explained 
either. A postulated hypothesis may be the modulation of 
the developing inflammatory reaction in the irradiated area 
by means of locally acting antibiotics. There are data which 
support the activation of the immunological response after 
the use of short-term radiotherapy [9–11]. The damaged cells 
from the tissues undergoing irradiation and immunological-
ly-inflammatory resident cells release factors which attract 
the cells from the blood and (or) lymphatic circulation [12, 
13]. The effect of the immunological response to the applied 
radiotherapy may concern not only the irradiated tissues, but 
also distant ones, which is known as the abscopal effect [3, 
14, 15]. The key factor here may be the fact that during the 
short break between the end of radiotherapy and surgery, 
a bactericidal, and also indirectly, anti-inflammatory agent is 
implanted into the area of the developing post-irradiation 
inflammatory reaction. As a result, this may affect the final 
shape of the immunological response, and thus, the obtained 
oncological results. 
In spite of the fact that the material comes from rando-
mized prospective studies, the results of the presented study 
must be interpreted with the utmost caution. This is the out-
come, first of all, of the fact that the study was retrospective. 
The length of the interval was not the outcome of random 
selection, and the delay in surgery might have concerned 
patients in whose cases the prognosis of survival was poorer 
on account of their comorbidities. In a large proportion of 
patients (20–23%), significant data was missing: the length of 
the resection margin, the invasion of blood and/or lymphatic 
vessels and the radicality of mesorectal resection were not 
analysed. Moreover, the disproportion in the numbers of the 
studied patient group, has significantly decreased the power 
of the sample. A small number of patients with a long interval 
between the end of radiotherapy and surgery does not allow 
for a definite conclusion whether the use of GRM affects the 
long-term oncological results.  
To sum up, the study results may suggest that the intraope-
rative use of GRM is beneficial as it decreases the risk of distant 
metastases and the prolongation of disease free survival, first 
of all in situations when surgery is performed within a short 
period of time (≤7 days) after the completion of irradiation. 
This, however, requires confirmation by a randomized and 
multi-centre clinical trial.        
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